Boehringer Ingelheim is one of the leading companies for development and manufacture of biopharmaceuticals by offering the entire production technology chain at its biopharmaceutical facilities in Biberach (Germany), in Fremont (USA) and in Vienna (Austria).
Among the world's top biopharmaceutical companies
All of the elements required for outsourcing biopharmaceutical development and manufacture, from high expression system to fill & finish, and patient convenient application systems can be found within the corporate capabilities of Boehringer Ingelheim in a so called One-Stop-Shop. At our large-scale production sites in Vienna, Austria and Biberach, Germany we have extablished a strong track record in regulatory approval since more than 25 years. So far 19 DNA-derived biopharmaceutical products have been successfully introduced to the market.
A well-filled R&D pipeline
One of our major efforts is the development of new biological entities (NBEs) for the treatment of diseases in the areas of:
Keeping Tumor Growth at Bay Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.Future of Medicine Could be Found in a Tiny Crystal Ball A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.Improving Delivery of Poorly Soluble Drugs Using Nanoparticles A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.Faster Drug Discovery? Startup develops more cost-effective test for assessing how cells respond to chemicals.New Mechanism of Antitumor Action Identified A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.Nanoparticles Deliver Tumor Suppressors to Damaged Livers UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.Experimental Combination Surprises with Anti-HIV Effectiveness A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.A New Type of Anticancer Agent Success in the development of a ?-tubulin specific inhibitor.Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs” In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.Versatile New Molecule-Building Technique Chemists at The Scripps Research Institute (TSRI) have devised a new and widely applicable technique for building potential drug molecules and other organic compounds.